Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 87 Show results per page	View Search Criteria \| Help With Results


1.		Maintenance Treatment With Liposomal Doxorubicin (Caelyx) in Metastatic Breast Cancer Patients

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Completed				18 to 90				Other				GEICAM 2001-01 NCT00128778

Last Modified: 5/14/2007


2.		Phase III Randomized Study of Doxorubicin HCl Liposome in Patients with AIDS-Related Kaposi's Sarcoma (Summary Last Modified 04/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				Not specified				Pharmaceutical / Industry				RPCI-DS-96-28 SEQUUS-30-38, NCI-G97-1241, NCT00002985

Last Modified: 6/1/1999


3.		Phase III, Randomized, Open-Label, Comparative Study of Liposomal Doxorubicin (DOXIL) versus Topotecan HCl in Patients with Epithelial Ovarian Carcinoma Following Failure of First Line, Platinum Based Chemotherapy (Summary Last Modified 06/1999)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				SEQUUS-30-49 NCI-V97-1257

Last Modified: 8/7/2007 First Published: 7/1/1998


4.		Phase III Randomized Study of Paclitaxel Versus Doxorubicin HCL Liposome in Patients with Advanced AIDS-Associated Kaposi's Sarcoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				NCI				E-1D96 AMC-009, SWOG-E1D96, CPMC-IRB-9905, NCT00003350, E1D96

Last Modified: 8/19/2008 First Published: 3/1/2001


5.		Phase III Randomized Study of Paclitaxel and Carboplatin With or Without Gemcitabine, Doxorubicin HCl Liposome, or Topotecan in Patients With Stage III or IV Ovarian Epithelial or Serous Primary Peritoneal Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				Any age				NCI				GOG-0182 SWOG-G0182, MRC-ICON5, ECOG-G0182, NCT00011986, GOG-0182

Last Modified: 1/25/2008 First Published: 8/1/2002


6.		Phase III Randomized Study of Carboplatin With or Without Pegylated Doxorubicin HCl Liposome in Patients With Platinum-Sensitive Recurrent Ovarian Epithelial or Primary Peritoneal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				Not specified				NCI				SWOG-S0200 S0200, NCT00043082


7.		Thalidomide + Dexamethasone vs. DOXIL (Doxorubicin HCl Liposome Injection) + Thalidomide + Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				CR004579 NCT00097981


8.		TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 and over				Pharmaceutical / Industry				TLK286.3024 NCT00102973


9.		Study of DOXIL/CAELYX and VELCADE or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				DOXIL MMY 3001 NCT00103506


10.		A Study Comparing the Combination of Doxil and Yondelis, to Doxil Alone for Subjects With Ovarian Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				ET743-OVA-301 ET743-OVA-301, NCT00113607

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute